natgillin/translations-raw huggingface dataset:
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leucoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including mycophenolate mofetil.
Pri bolnikih, zdravljenih z imunosupresivi, vključno z mofetilmikofenolatom, so poročali o primerih nefropatije, povezane z virusom BK, kot tudi progresivne multifokalne levkoencefalopatije (PML), povezane z virusom JC.
Cases of BK virus-associated nephropathy, as well as cases of JC virus-associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Rapamune.
Pri bolnikih, zdravljenih z imunosupresivi, med drugim tudi z zdravilom Rapamune, so poročali o primerih nefropatije, povezane z virusom BK, in o primerih progresivne multifokalne levkoencefalopatije (PML), povezane z virusom JC.
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12,506 patients, 0.15%) than in control groups (7 cases from 10,212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029).
V meta-analizi nadzorovanih kliničnih preskušanj so o raku sečnega mehurja poročali pogosteje pri bolnikih, ki so prejemali pioglitazon (19 primerov od 12.506 bolnikov, 0,15 %) kot pri bolnikih v kontrolnih skupinah (7 primerov od 10.212 bolnikov, 0,07 %), HR=2,64 (95 % IZ 1,11-6,31, P=0,029).
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12506 patients, 0.15%) than in control groups (7 cases from
O primerih raka mehurja so pogosteje poročali v meta-analizi kontroliranih kliničnih preskušanjih s pioglitazonom (19 primerov od 12.506 bolnikov, 0,15 %) kot v kontrolnih skupinah (7 primerov od
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12506 patients, 0.15%) than in control groups (7 cases from
O primerih raka mehurja, so pogosteje poročali v meta-analizi kontroliranih kliničnih preskušanjih s pioglitazonom (19 primerov od 12.506 bolnikov, 0,15 %) kot v kontrolnih skupinah (7 primerov od
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12506 patients, 0.15%) than in control groups (7 cases from 10212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029).
O primerih raka sečnega mehurja so pogosteje poročali v meta-analizi kontroliranih kliničnih preskušanjih s pioglitazonom (19 primerov od 12.506 bolnikov, 0,15%) kot v kontrolnih skupinah (7 primerov od 10.212 bolnikov, 0,07%) HR = 2,64 (95% IZ 1,11-6,31, P = 0,029).
Cases of bleeding events with a fatal outcome have been observed.
Zabeležili so krvavitve, ki so se končale s smrtjo.
Cases of bleeding events with a fatal outcome have been observed.
Zabeležili so primere krvavitev s smrtnim izidom.
Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen.
Poročali so o primerih dehiscence bronhialnih anastomoz, večinoma smrtnih, pri bolnikih z novo transplantiranimi pljuči, ki so uporabljali sirolimus kot del imunosupresivnega zdravljenja.
Cases of capillary leak syndrome have been reported in postmarketing experience after administration of G-CSF or derivatives.
V obdobju trženja zdravila so poročali o primerih sindroma kapilarne prepustnosti po uporabi G-CSF ali derivatov.
Cases of capillary leak syndrome have been reported in the post marketing setting with granulocyte colony- stimulating factor use.
V obdobju trženja zdravila so poročali o primerih sindroma kapilarne prepustnosti med uporabo granulocitne kolonije stimulirajočega faktorja.
Cases of capillary leak syndrome have been reported in the post marketing setting with granulocyte colony-stimulating factor use.
O primerih sindroma povečane prepustnosti kapilar so poročali v okviru izkušenj po začetku trženja ob uporabi granulocitne kolonije spodbujajočega faktorja.
Cases of capillary leak syndrome have been reported in the post marketing setting with granulocyte colony-stimulating factor use.
V obdobju trženja zdravila so poročali o primerih sindroma kapilarne prepustnosti med uporabo granulocitne kolonije stimulirajočega faktorja.
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac failure.
Poročali so o primerih srčnega popuščanja med uporabo pioglitazona v kombinaciji z insulinom, zlasti pri bolnikih z dejavniki tveganja za srčno popuščanje.
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure.
Ob uporabi pioglitazona v kombinaciji z insulinom so poročali o primerih srčnega popuščanja, predvsem pri bolnikih z dejavniki tveganja za razvoj srčnega popuščanja.
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure.
Poročali so o primerih srčnega popuščanja med uporabo pioglitazona v kombinaciji z insulinom, zlasti pri bolnikih z dejavniki tveganja za srčno popuščanje..
Cases of convulsion, exacerbation of convulsion, increased excitability and irritability have been observed during co- administration of levodopa and sapropterin in BH4-deficient patients (see section 4.5).
Pri sočasni uporabi levodope in saproterina so pri bolnikih s pomanjkanjem BH4 poročali o konvulzijah, poslabšanju konvulzij ter povečani razdražljivosti in preobčutljivosti (glejte poglavje 4.5).
Cases of convulsion, exacerbation of convulsion, increased excitability and irritability have been observed during co- administration of levodopa and sapropterin in BH4-deficient patients.
Pri bolnikih s pomanjkanjem BH4 so med sočasnim dajanjem levodope in sapropterina opazili primere konvulzij, ponovnega pojava konvulzij, povečano razdražljivost in preobčutljivost.
Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.
O primerih kalcifikacije roženice so poročali v zelo redkih primerih, pri nekaterih bolnikih z znatnimi poškodbami roženice, ki so uporabljali kapljice za oko, ki vsebujejo fosfate.
Cases of Cushing’s syndrome and adrenal suppression have been reported.
Opisani so primeri Cushingovega sindroma in zavrtja nadledvičnih žlez.
Cases of decreased bone density and osteoporosis have been reported in paediatric patients with severe chronic neutropenia receiving chronic treatment with filgrastim.
Pri pediatričnih bolnikih s hudo kronično nevtropenijo, ki prejemajo kronično zdravljenje s filgrastimom, so poročali o primerih zmanjšane gostote kosti in osteoporoze.
Cases of Ehlers-Danlos like syndrome and vascular disorders on elbows have been reported in children treated with high doses of different cysteamine preparations (cysteamine chlorhydrate or cystamine or cysteamine bitartrate) mostly above the maximal dose 1.95 g/m2/day.
Pri otrocih, zdravljenih z velikimi odmerki različnih pripravkov cisteamina (cisteaminijev klorhidrat ali cistamin ali cisteaminijev bitartrat), večinoma večjimi od največjega odmerka 1,95 g/m2/dan, so poročali o primerih Ehlers-Danlosovemu podobnega sindroma in vaskularnih motnajh na komolcih.
Cases of encephalopathy have been rarely observed after levetiracetam administration.
Po uporabi levetiracetama so redko opazili primere encefalopatije.
Cases of fatal intracranial haemorrhage have been reported in some patients with brain metastases.
Pri nekaterih bolnikih z možganskimi zasevki so poročali o primerih smrtnih znotrajlobanjskih krvavitev.
Cases of fistula formation, sometimes associated with tumour necrosis and regression, in some cases with fatal outcomes, have been reported.
Poročali so o primerih nastanka fistule, ki so bili včasih povezani z nekrozo in regresijo tumorja, v nekaterih primerih s smrtnim izidom.
Cases of foetal abnormalities in women treated with bevacizumab alone or in combination with known embryotoxic chemotherapeutics have been observed (see section 4.6 )
v obdobju po prihodu zdravila na trg so opazili primere nenormalnosti pri plodu, če je nosečnica jemala zdravilo Avastin samo ali v kombinaciji s kemoterapijo, za katero je znano, da je embriotoksična (glejte poglavje 4.6)
Cases of gastro-intestinal perforation have been reported in patients receiving Gazyvaro, mainly in NHL.
Pri bolnikih, zdravljenih z zdravilom Gazyvaro, so poročali o primerih gastrointestinalnih perforacij, večinoma pri NHL.
Cases of GI perforation have been reported in the postauthorisation period in patients using methylnaltrexone bromide.
V obdobju po izdaji dovoljenja za promet so pri bolnikih, ki so prejemali metilnaltreksonijev bromid, poročali o primerih gastrointestinalne perforacije.
Cases of haemorrhage have been reported in postmarketing period (including patients with or without anticoagulant therapy or other drugs that could cause bleeding).
V obdobju trženja zdravila so poročali o primerih krvavitev (vključno pri bolnikih, ki niso zdravljeni z antikoagulanti, in tistih, ki so zdravljeni z antikoagulanti ali drugimi zdravili, ki bi lahko povzročili krvavitve).
Cases of hepatic failure, some with a fatal outcome, were observed in <1% of solid tumor patients treated with sunitinib.
Primere odpovedi delovanja jeter, nekatere s smrtnim izidom, so opažali pri < 1 % bolnikov s čvrstimi tumorji, ki so se zdravili s sunitinibom.
Cases of hepatitis B reactivation have been reported in patients receiving the MabThera intravenous formulation including fulminant hepatitis with fatal outcome.
Pri bolnikih, ki so prejemali zdravilo MabThera, so poročali o reaktivaciji virusa hepatitisa B, vključno s fulminantnim hepatitisom s smrtnim izidom.
Cases of hepatitis B reactivation have been reported in patients treated with Gazyvaro (see section 4.4).
Pri bolnikih, zdravljenih z zdravilom Gazyvaro, so bili opisani primeri reaktivacije virusa hepatitisa B (glejte poglavje 4.4).
Cases of hepatitis B reactivation, including those with a fatal outcome, have been reported in rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis patients receiving MabThera.
Pri bolnikih z revmatoidnim artritisom, granulomatozo s poliangiitisom in mikroskopskim poliangiitisom, ki so prejemali zdravilo MabThera, so poročali o primerih reaktivacije hepatitisa B, vključno s smrtnim izidom.
Cases of hepatotoxicity occurred in less than 1% of patients receiving ceritinib in clinical studies.
Hepatotoksičnost se je pojavila pri manj kot 1 % bolnikov, ki so prejemali ceritinib v kliničnih študijah.
Cases of herpes zoster in clinical studies
Primeri pasavca (herpes zoster) v kliničnih študijah
Cases of hyperglycaemia (all grades) have been reported in less than 10% of patients treated with ceritinib in clinical studies; grade 3-4 hyperglycaemia was reported in 5% of patients.
O primerih hiperglikemije (katerekoli stopnje) so poročali pri manj kot 10 % bolnikov, ki so prejemali ceritinib v kliničnih študijah, o hiperglikemiji 3.-4. stopnje pa so poročali pri 5 % bolnikov.
Cases of hyperglycaemia have been reported with Apidra when used with CSII (see section 4.4) that has led to Diabetic Ketoacidosis (DKA); most of the cases were related to handling errors or pump system failure.
Med uporabo zdravila Apidra v CSII so bili opisani primeri hiperglikemije (glejte poglavje 4.4), ki so povzročili diabetično ketoacidozo (DKA); večina primerov je bila povezana z napakami pri ravnanju ali z odpovedjo sistema s črpalko.
Cases of hypersensitivity reactions have been reported, as early as with the first dose, during post-marketing surveillance (see section 4.8).
V obdobju trženja zdravila so poročali o primerih preobčutljivostnih reakcij že pri prvem odmerku (glejte poglavje 4.8).
Cases of hyperthyroidism, some followed by hypothyroidism, and cases of thyroiditis have been uncommonly reported in clinical trials and through post-marketing experience.
V kliničnih preskušanjih in v obdobju trženja so bili opisani občasni primeri hipertiroidizma, ki mu je včasih sledil hipotiroidizem, in primeri tiroiditisa.
Cases of hyponatracemia have been reported, mostly associated with dehydration, vomiting and pneumonia
Opisani so bili primeri hiponatriemije, večinoma povezani z dehidracijo, bruhanjem in pljučnico.
Cases of ILD have been reported in patients treated with IMBRUVICA.
Pri bolnikih, ki so jemali zdravilo IMBRUVICA so poročali o primerih ILD.
Cases of ileus have been uncommonly reported (see section 4.8).
Občasno so poročali o primerih zapore črevesja.
Cases of impaired wound healing have been reported during sunitinib therapy.
Poročali so o primerih oteženega celjenja ran med zdravljenjem s sunitinibom.
Cases of interstitial lung disease (ILD), both fatal and non-fatal, have been reported, mainly from the Japanese population.
Predvsem pri japonski populaciji so poročali o primerih intersticijske pljučne bolezni (ILD – Interstitial Lung Disease), in sicer s smrtnim izidom in brez njega.
Cases of interstitial lung disease (including pneumonitis and infrequently bronchiolitis obliterans organising pneumonia (BOOP) and pulmonary fibrosis), some fatal, with no identified infectious aetiology have occurred in patients receiving immunosuppressive regimens including Rapamune.
Pri bolnikih, ki so se zdravili po imunosupresivni shemi, vključno z zdravilom Rapamune, so se pojavili primeri intersticijske bolezni pljuč (vključno s pnevmonitisom, redko z bronhiolitis obliterans organizirano pljučnico (BOOP – Bronchiolitis Obliterans Organising Pneumonia) in pljučno fibrozo), nekateri s smrtnim izidom, brez identificirane infekcijske etiologije.
Cases of interstitial lung disease have been reported, with the majority of patients from the Japanese population.
Poročali so o primerih intersticijske pljučne bolezni, pri čemer je bila večina bolnikov pripadnikov japonske populacije.
Cases of interstitial lung disease, some with fatal outcome have been reported.
Poročali so o primerih intersticijske bolezni pljuč, nekateri so bili smrtni.
Cases of jaundice and non-infectious hepatitis, some with features of autoimmune hepatitis, have been observed in the post-marketing experience of infliximab.
Med izkušnjami v obdobju trženja infliksimaba v obdobju trženja so opažali primere zlatenice in neinfekcijskega hepatitisa in nekateri od njih so imeli značilnosti avtoimunskega hepatitisa.
Cases of lactic acidosis, sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of combination nucleoside analogue therapy in patients with HIV.
Pri zdravljenju bolnikov, okuženih z virusom HIV, s kombinacijo nukleozidnih analogov, so poročali o primerih laktacidoze, ki je bila včasih smrtna in ponavadi povezana s hudo hepatomegalijo in jetrno steatozo.
Cases of leukaemia have been reported in patients treated with Simponi.
Pri bolnikih, zdravljenih z zdravilom Simponi, so poročali o primerih levkemije.
Cases of liver damage (hepatocellular, cholestatic and mixed) and autoimmune hepatitis were observed.
Opazili so primere poškodbe jeter (hepatocelularne, holestatske in mešane) in avtoimunega hepatitisa.
Cases of liver injury, including hepatic failure (few cases were exceptionally reported with fatal outcome or liver transplantation in patients with hepatic risk factors), elevations of liver enzymes exceeding 10 times upper limit of normal, hepatitis and jaundice have been reported in patients treated with Thymanax in the post-marketing setting (see section 4.8).
V času po prihodu zdravila na trg so pri bolnikih, zdravljenih z zdravilom Thymanax, poročali o primerih poškodb jeter, vključno z odpovedjo jeter (pri bolnikih s prisotnimi dejavniki tveganja za poškodbo jeter so izjemoma poročali o nekaj primerih s smrtnim izidom ali transplantacijo jeter), zvišanjih jetrnih encimov nad 10-kratno zgornjo mejo normalnih vrednosti, hepatitisu in zlatenici (glejte poglavje 4.8).
Cases of liver injury, including hepatic failure (few cases were exceptionally reported with fatal outcome or liver transplantation in patients with hepatic risk factors), elevations of liver enzymes exceeding 10 times upper limit of normal, hepatitis and jaundice have been reported in patients treated with Valdoxan in the post-marketing setting (see section 4.8).
V času po prihodu zdravila na trg so pri bolnikih, zdravljenih z zdravilom Valdoxan, poročali o primerih poškodb jeter, vključno z odpovedjo jeter (pri bolnikih s prisotnimi dejavniki tveganja za poškodbo jeter so izjemoma poročali o nekaj primerih s smrtnim izidom ali transplantacijo jeter), zvišanjih jetrnih encimov nad 10-kratno zgornjo mejo normalnih vrednosti, hepatitisu in zlatenici (glejte poglavje 4.8).
Cases of lymphoma occurred at an incidence rate of 0.05 per 100 patient-years and melanoma at an incidence rate of 0.08 per 100 patient-years with Cimzia in rheumatoid arthritis clinical trials (see section 4.4).
Limfom se je v okviru kliničnih raziskav za zdravilo Cimzia pri bolnikih z revmatoidnim artritisom pojavljal s stopnjo incidence 0,05 na 100 bolnikovih let, melanom pa s stopnjo 0,08 na 100 bolnikovih let (glejte poglavje 4,4).
Cases of malignancies, including lymphoma, have also been reported in the post-marketing setting (see section 4.4).
V obdobju trženja so poročali tudi o primerih malignih bolezni, vključno z limfomom (glejte poglavje 4.4).
Cases of misuse, abuse and dependece have been reported.
Poročali so o primerih nepravilne uporabe, zlorabe in odvisnosti.
Cases of misuse, abuse and dependence have been reported.
Poročali so o primerih nepravilne uporabe, zlorabe in odvisnosti.
Cases of myopathy and/or rhabdomyolysis, some with acute renal failure, have been reported.
Poročali so o primerih miopatije in/ali rabdomiolize, v nekaterih primerih z akutno odpovedjo ledvic.
Cases of myopathy have been reported in patients treated with ZYTIGA.
Pri bolnikih, ki so se zdravili z zdravilom ZYTIGA so poročali o primerih miopatije.
Cases of nephrotic syndrome with different underlying nephropathies including collapsing focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranoproliferative glomerulonephritis (MPGN) and membranous glomerulopathy (MGN) have been reported during treatment with interferon beta products.
Med zdravljenjem z zdravili, ki vsebujejo interferon beta, so poročali o primerih nefrotskega sindroma pri različnih predhodnih nefropatijah, vključno s fokalno segmentno glomerulosklerozo (kolapsno spremenjeni glomeruli), glomerulonefritisom z minimalnimi spremembami, membranoproliferativnim glomerulonefritisom in membransko glomerulopatijo.
Cases of nephrotic syndrome with different underlying nephropathies including collapsing focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranoproliferative glomerulonephritis (MPGN) and membranous glomerulopathy (MGN) have been reported during treatment with interferon-beta products.
Med zdravljenjem z zdravili, ki vsebujejo interferon beta, so poročali o primerih nefrotskega sindroma z različnimi osnovnimi nefropatijami, vključno s kolapsno fokalno segmentno glomerulosklerozo (FSGS), boleznijo minimalnih sprememb (MCD, minimal change disease), membranoproliferativnim glomerulonefritisom (MPGN) in membransko glomerulopatijo (MGN).
Cases of new or exacerbations of Crohn’s disease and ulcerative colitis have been reported.
Poročali so o novih primerih ali poslabšanjih Crohnove bolezni in ulceroznega kolitisa.
Cases of non-congenital lens opacities without impact on vision have been reported in paediatric patients treated with ivacaftor monotherapy.
Pri pediatričnih bolnikih, zdravljenih z monoterapijo z ivakaftorjem, so poročali o primerih ne-prirojenih motnjav leče brez vpliva na vid.
Cases of non-cuSCC have been reported in clinical trials where patients received vemurafenib.
Pri bolnikih, ki so prejemali vemurafenib v kliničnih preskušanjih, so poročali o primerih ploščatoceličnega karcinoma, ki se ne nahaja na koži.
Cases of non-cuSCC have been reported in patients receiving vemurafenib while enrolled in clinical trials.
Pri bolnikih, ki so prejemali vemurafenib v kliničnih preskušanjih, so poročali o primerih ploščatoceličnega karcinoma, ki se ne nahaja na koži.
Cases of non-mandibular osteonecrosis have been observed in Avastin treated paediatric patients (see section 4.8, Paediatric population).
pri zdravljenju pediatričnih bolnikov z zdravilom Avastin so opazili primere osteonekroze izven spodnje čeljustnice (glejte poglavje 4.8, Pediatrični bolniki)
Cases of ONJ have been reported in cancer patients treated with Zaltrap, several of whom had received prior or concomitant treatment with intravenous bisphosphonates, for which ONJ is an identified risk.
O osteonekrozi čeljustnic so poročali pri bolnikih z rakom, zdravljenih z zdravilom Zaltrap, od katerih se jih je več predhodno ali sočasno zdravilo z intravenskimi difosfonati, za katere je osteonekroza čeljustnic ugotovljeno tveganje.
Cases of ONJ have been reported in patients treated with SUTENT, most of which occurred in patients who had identified risk factors for ONJ, in particular exposure to intravenous bisphosphonates and/or a history of dental disease requiring invasive dental procedures (see also section 4.4).
Pri bolnikih, zdravljenih z zdravilom SUTENT, so poročali o primerih osteonekroze čeljustnic, večinoma pri bolnikih s prisotnimi znanimi dejavniki tveganja za osteonekrozo čeljustnic, zlasti izpostavljenost intravenskim bisfosfonatom in/ali anamneza zobne bolezni, ki je zahtevala invazivne zobozdravstvene posege (glejte tudi poglavje 4.4).
Cases of ONJ have been reported in the post- marketing setting for Zoledronic acid Teva Pharma.
O osteonekrozi čeljusti so poročali tudi v okviru uporabe v času trženja zdravila Zoledronska kislina Teva Pharma.
Cases of ONJ have been reported in the post- marketing setting for zoledronic acid.
O osteonekrozi čeljusti so poročali tudi v okviru uporabe v času trženja zoledronske kisline.
Cases of opioid withdrawal syndrome have been reported in the naloxegol clinical programme (DSM- 5).
V kliničnem programu z naloksegolom so bili opisani primeri sindroma odtegnitve opioidov (DSM-5).
Cases of Osteonecrosis of the Jaw (ONJ) have been reported in patients treated with Avastin, most of which occurred in patients who had identified risk factors for ONJ, in particular exposure to intravenous bisphosphonates and/or a history of dental disease requiring invasive dental procedures (see also section 4.4)
pri bolnikih, zdravljenih z zdravilom Avastin, so poročali o primerih osteonekroze čeljustnic; v večini primerov je šlo za bolnike, pri katerih so bili prisotni znani dejavniki tveganja za osteonekrozo čeljustnic, zlasti izpostavljenost intravenskim difosfonatom in/ali anamneza zobne bolezni, ki je zahtevala invazivne zobozdravstvene posege (glejte tudi poglavje 4.4)
Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, including zoledronic acid (see section 4.4).
O osteonekrozi čeljusti so poročali predvsem pri bolnikih z rakom, zdravljenih z zdravili, ki zavirajo resorpcijo kosti, vključno z zoledronsko kislino (glejte poglavje 4.4).
Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as zoledronic acid (see section 4.4).
O osteonekrozi čeljusti so poročali predvsem pri bolnikih z rakom, zdravljenih z zdravili, ki zavirajo resorpcijo kosti, kot je zoledronska kislina (glejte poglavje 4.4).
Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as zoledronic acid (see section 4.4).
Predvsem pri bolnikih z rakom, zdravljenih z zdravili, ki zavirajo resorpcijo kosti, kot je zoledronska kislina, so poročali o primerih osteonekroze (predvsem čeljustnic).